Recent Securities Litigations

Bristol-Myers Squibb Company Common Stock (NYSE: BMY)

51 Days left to seek lead plaintiff status.

Company Name:Bristol-Myers Squibb Company Common Stock
Stock Symbol:NYSE: BMY
Class Period Start:02/22/2019
Class Period End (inclusive):10/06/2021
Filing Deadline:12/06/2021

On January 3, 2019, BMS and Celgene agreed to a merger under which Celgene shareholders would receive $50 in cash, one share of BMS common stock, and one CVR for each share of Celgene common stock. Each CVR would provide holders a contingent right to receive $9 in cash if certain milestones were reached, which consisted of FDA approval of three applications by certain deadline dates. On January 1, 2021, BMS announced that one of the deadlines had not been met and terminated the CVRs.
The lawsuit charges BMS with failing to take diligent efforts to meet the milestones, as required by the CVR agreement, in order to avoid paying the CVR buyout. As a result, the statements in the Joint Proxy concerning the efforts BMS would make to meet the milestones, the likelihood that the milestones would be met and the purported value of the CVRs were materially false and misleading when made.

Bristol-Myers Squibb Company Common Stock (NYSE: BMY) Claim Form

Name(Required)
Address
Consent(Required)
This field is for validation purposes and should be left unchanged.